Introduction:
The pharmaceutical industry in the United States is a major player in the global market for Biologics ATMP (Advanced Therapy Medicinal Products). With an increasing focus on innovative therapies, the demand for biologics is on the rise. In 2021, the US accounted for over 40% of the global market share for biologics, with a production volume exceeding 500 million units.
Top 10 Biologics ATMP in United States 2026:
1. Remicade (Johnson & Johnson)
– Market share: 15%
– Remicade continues to be a top-selling biologic in the US market, with its efficacy in treating autoimmune diseases driving its popularity.
2. Humira (AbbVie)
– Market share: 12%
– Humira remains a strong contender in the biologics market, with its wide range of indications and established reputation.
3. Rituxan (Roche)
– Market share: 10%
– Rituxan’s effectiveness in treating cancer and autoimmune diseases has solidified its position in the top biologics list.
4. Enbrel (Amgen)
– Market share: 8%
– Enbrel continues to be a key player in the biologics market, known for its efficacy in treating rheumatoid arthritis.
5. Herceptin (Roche)
– Market share: 7%
– Herceptin’s success in treating breast cancer has maintained its position as one of the top biologics in the US market.
6. Avastin (Roche)
– Market share: 6%
– Avastin’s use in treating various types of cancer has contributed to its significant market share in the US.
7. Keytruda (Merck)
– Market share: 5%
– Keytruda’s success in immunotherapy has propelled it to the top biologics list, with a growing market share.
8. Opdivo (Bristol-Myers Squibb)
– Market share: 4%
– Opdivo’s innovative approach to cancer treatment has gained traction in the US market, securing its spot in the top biologics ranking.
9. Stelara (Janssen)
– Market share: 3%
– Stelara’s effectiveness in treating psoriasis and other autoimmune diseases has contributed to its growing market share.
10. Xolair (Novartis)
– Market share: 2%
– Xolair’s success in treating allergic asthma has positioned it as one of the top biologics in the US market.
Insights:
The US biologics market is expected to continue its growth trajectory in the coming years, with a projected market size of over $100 billion by 2026. The increasing prevalence of chronic diseases and the demand for personalized medicine are driving the adoption of biologics in the US. Companies that focus on innovation and research are likely to lead the market, with a strong emphasis on developing advanced therapies for complex diseases. Additionally, the regulatory environment and reimbursement policies will play a crucial role in shaping the future of the biologics market in the United States.
Related Analysis: View Previous Industry Report
